TY - JOUR
T1 - Oral administration of PET tracers
T2 - Current status
AU - Salvi de Souza, Giordana
AU - Mantovani, Dimitri B. A.
AU - Mossel, Pascalle
AU - Haarman, Bartholomeus C. M.
AU - Marques da Silva, Ana Maria
AU - Boersma, Hendrikus H.
AU - Furini, Cristiane R. G.
AU - Lammertsma, Adriaan A.
AU - Tsoumpas, Charalampos
AU - Luurtsema, Gert
N1 - Funding Information:
This work is supported by CNEN ( Comissão Nacional de Energia Nuclear ) of Brazil and the Abel Tasman Talent Program (ATTP) of the Graduate School of Medical Sciences of the University of Groningen , the Netherlands.
Publisher Copyright:
© 2023 The Authors
PY - 2023/5/1
Y1 - 2023/5/1
N2 - The oral route is the most widely used and preferable way of drug administration. Several pharmacokinetic processes play a role in the distribution of administered drugs. Therefore, accurate quantification of absorption, distribution, metabolism, excretion, and characterisation of drug kinetics after oral administration is extremely important for developing new human drugs. In vivo methods, such as gamma-scintigraphy, magnetic resonance imaging (MRI), and positron emission tomography (PET), have been used to analyse gastrointestinal tract (GIT) absorption behaviour. This scoping review provides an overview of PET studies that used oral tracer administration. A systematic literature search was performed using PubMed, EMBASE, Scopus, Science Direct, and Web of Science databases. Extensive variation between these studies was seen concerning acquisition protocols, quantification methods, and pharmacokinetic outcome parameters. Studies in humans indicate that it takes 10 to 30 min for the tracer to be in the intestine and about 100 min to reach its maximum concentration in the brain. In rodent studies, different pharmacokinetic parameters for the brain, blood, and GIT were estimated, showing the potential of PET to measure the absorption and distribution of drugs and pharmaceuticals non-invasively. Finally, regarding radiation protection, oral administration has a higher absorbed dose in GIT and, consequently, a higher effective dose. However, with the recent introduction of Long Axial Field of View (LAFOV) PET scanners, it is possible to reduce the administered dose, making oral administration feasible for routine clinical studies.
AB - The oral route is the most widely used and preferable way of drug administration. Several pharmacokinetic processes play a role in the distribution of administered drugs. Therefore, accurate quantification of absorption, distribution, metabolism, excretion, and characterisation of drug kinetics after oral administration is extremely important for developing new human drugs. In vivo methods, such as gamma-scintigraphy, magnetic resonance imaging (MRI), and positron emission tomography (PET), have been used to analyse gastrointestinal tract (GIT) absorption behaviour. This scoping review provides an overview of PET studies that used oral tracer administration. A systematic literature search was performed using PubMed, EMBASE, Scopus, Science Direct, and Web of Science databases. Extensive variation between these studies was seen concerning acquisition protocols, quantification methods, and pharmacokinetic outcome parameters. Studies in humans indicate that it takes 10 to 30 min for the tracer to be in the intestine and about 100 min to reach its maximum concentration in the brain. In rodent studies, different pharmacokinetic parameters for the brain, blood, and GIT were estimated, showing the potential of PET to measure the absorption and distribution of drugs and pharmaceuticals non-invasively. Finally, regarding radiation protection, oral administration has a higher absorbed dose in GIT and, consequently, a higher effective dose. However, with the recent introduction of Long Axial Field of View (LAFOV) PET scanners, it is possible to reduce the administered dose, making oral administration feasible for routine clinical studies.
KW - Gastrointestinal tract
KW - Oral administration
KW - Pharmacokinetics
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=85153032001&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2023.04.008
DO - 10.1016/j.jconrel.2023.04.008
M3 - Review article
C2 - 37031742
SN - 0168-3659
VL - 357
SP - 591
EP - 605
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -